Clinical Trial Update: Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib for myeloproliferative disorders; the study has completed and results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Hypereosinophilic Syndrome
• Myelodysplastic Syndromes
• Myelofibrosis
• Myelomonocytic Leukemia
• Polycythemia Vera
• Systemic Mastocytosis

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2019-05-06